Lido Advisors LLC lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 7,188 shares of the medical research company’s stock after selling 105 shares during the period. Lido Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,969,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in TMO. Vanguard Group Inc lifted its stake in shares of Thermo Fisher Scientific by 1.2% in the 3rd quarter. Vanguard Group Inc now owns 29,271,095 shares of the medical research company’s stock worth $7,144,489,000 after purchasing an additional 347,836 shares during the period. BlackRock Inc. lifted its stake in shares of Thermo Fisher Scientific by 4.1% in the 1st quarter. BlackRock Inc. now owns 27,251,678 shares of the medical research company’s stock worth $7,459,327,000 after purchasing an additional 1,074,400 shares during the period. Oregon Public Employees Retirement Fund lifted its stake in shares of Thermo Fisher Scientific by 44,296.5% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 19,565,960 shares of the medical research company’s stock worth $87,000 after purchasing an additional 19,521,889 shares during the period. FMR LLC lifted its stake in shares of Thermo Fisher Scientific by 33.4% in the 4th quarter. FMR LLC now owns 8,671,713 shares of the medical research company’s stock worth $1,940,642,000 after purchasing an additional 2,172,574 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 9.4% in the 4th quarter. Geode Capital Management LLC now owns 4,897,714 shares of the medical research company’s stock worth $1,094,013,000 after purchasing an additional 422,625 shares during the period. Institutional investors and hedge funds own 87.96% of the company’s stock.

NYSE TMO traded down $1.74 on Wednesday, reaching $283.31. 7,861 shares of the stock were exchanged, compared to its average volume of 1,645,002. Thermo Fisher Scientific Inc. has a one year low of $202.83 and a one year high of $288.07. The stock has a market cap of $113.70 billion, a price-to-earnings ratio of 25.46, a PEG ratio of 1.85 and a beta of 1.08. The company has a current ratio of 1.69, a quick ratio of 1.16 and a debt-to-equity ratio of 0.61.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 24th. The medical research company reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.74 by $0.07. Thermo Fisher Scientific had a net margin of 12.89% and a return on equity of 17.06%. The company had revenue of $6.13 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter last year, the business earned $2.50 EPS. The firm’s revenue was up 4.6% compared to the same quarter last year. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 12.2 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 16th. Shareholders of record on Friday, June 14th will be paid a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend is Thursday, June 13th. Thermo Fisher Scientific’s payout ratio is 6.83%.

In other Thermo Fisher Scientific news, Director C Martin Harris sold 275 shares of the stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $270.73, for a total transaction of $74,450.75. Following the completion of the sale, the director now directly owns 6,433 shares of the company’s stock, valued at approximately $1,741,606.09. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 50,713 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $273.21, for a total transaction of $13,855,298.73. Following the sale, the chief executive officer now directly owns 302,193 shares of the company’s stock, valued at $82,562,149.53. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 53,488 shares of company stock worth $14,600,474. 0.45% of the stock is owned by company insiders.

TMO has been the topic of several recent research reports. Barclays increased their price objective on shares of Thermo Fisher Scientific from $295.00 to $300.00 and gave the stock an “overweight” rating in a research note on Monday, March 18th. Deutsche Bank increased their price objective on shares of Thermo Fisher Scientific from $275.00 to $300.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. UBS Group increased their price objective on shares of Thermo Fisher Scientific to $305.00 and gave the stock a “buy” rating in a research note on Monday, March 25th. BTIG Research increased their price objective on shares of Thermo Fisher Scientific to $310.00 and gave the stock a “buy” rating in a research note on Tuesday, March 26th. Finally, Robert W. Baird increased their price objective on shares of Thermo Fisher Scientific from $270.00 to $288.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 26th. Two analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $295.92.

TRADEMARK VIOLATION NOTICE: This piece of content was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://theolympiareport.com/2019/06/12/thermo-fisher-scientific-inc-nysetmo-shares-sold-by-lido-advisors-llc.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: How a Put Option Works

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.